Volume 107, Issue 1-6 pp. 585-592

Development of resistance and cross-resistance in Pseudomonas aeruginosa exposed to subinhibitory antibiotic concentrations

Y. L. WU

Y. L. WU

Schools of Pharmacy, The Queen's University of Belfast, Belfast

Search for more papers by this author
E. M. SCOTT

Corresponding Author

E. M. SCOTT

Schools of Pharmacy, The Queen's University of Belfast, Belfast

Schools of Pharmacy, Medical Biology Centre, The Queen's University of Belfast, 97 Lisburn Road, Belfast BT9 7BL, Northern Ireland, UK.Search for more papers by this author
A. LI WAN PO

A. LI WAN PO

School of Life Sciences, Aston, University of Birmingham, Birmingham, United Kingdom

Search for more papers by this author
V N. TARIQ

V N. TARIQ

Schools of Biology & Biochemistry, The Queen's University of Belfast, Belfast

Search for more papers by this author
First published: 15 August 2009
Citations: 20

Abstract

The purpose of this study was to compare resistance and cross-resistance development in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients to commonly used antipseudomonal antibiotics. Isolates were repeatedly exposed to subinhibitory concentrations of either azlocillin, tobramycin, ceftazidime or ciprofloxacin. On 10 consecutive occasions, samples were removed from the half-MIC well of a microtitre plate and regrown in drug-free medium to provide the next inoculum for MIC determination. The increase in MIC at the end of the treatment period was significant (p<0.05) for all selecting antibiotics. Cross-resistance to unrelated antibiotics was not observed, but was significant (p<0.05) in all β-lactams (ticarcillin, piperacillin, ceftazidime and cefsulodin) studied where azlocillin was the selecting antibiotic. The addition of clavulanic acid to ticarcillin and of tazobactam to piperacillin had no effect on cross-resistance. The development of resistance to azlocillin was associated with increased β-lactamase activity and a change in isoelectric point of the β-lactamases. The result of this study supports a rotational policy for antipseudomonal antibiotics in CF patients.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.